Biotech
@ej23ny
Followers
2,586
Following
31
Media
3,415
Statuses
13,943
disclaimer: No investment advice and tweets are my opinion or research that I have done. Do your own research before investing in stock market.
Florida, USA
Joined August 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
DEAR MYLOVE LINGORM
• 1093114 Tweets
#Narin
• 182672 Tweets
CHARLOTTE X TIKTOKLIVE99
• 95920 Tweets
#光る君へ
• 81106 Tweets
#FinalMGSBR2025xENGFA
• 55726 Tweets
#レカぺだけ歩こうJO1
• 50736 Tweets
プロジェクトKV
• 42665 Tweets
Zapatero
• 39756 Tweets
İdam
• 24826 Tweets
#鉄腕DASH
• 21083 Tweets
SUNa ALL KAIRAIN
• 19876 Tweets
ポルノグラフィティ
• 19227 Tweets
#ブラックペアン
• 16583 Tweets
#にじカラオケ祭
• 12652 Tweets
Edmundo
• 10498 Tweets
源氏物語
• 10225 Tweets
Kostic
• 10082 Tweets
$MREO IM HOLDING FULL POSTITION. NOT SELLING ANY SHARES BELOW $10
$XBI $IBB
7
2
60
$MREO majority of folks are clueless what me and
@wkissel
has done behind the scenes in the past 2 years. Thank you to
@wkissel
smart and great man. Also I want to thank
@semodough
for posting great DD
$MREO I missed my add yesterday. I had it teed up in the morning, but brain-farted. Never got the order in. My current avg cost is $2.30. Thank you to
@PharmDabbler
@Pharmdca
@TedKaridis
@ej23ny
(and varoius others) for your collective wisdom and all the information you provide.
2
0
20
8
4
57
$MREO hired new VP Head of Legal experienced in M&A. She was VP Head of Legal $ALBO who was acquired by $IPSEY for +$1Bn.
I wonder Why would MEREO hire experienced M&A lawyer now ? unless they are negotiating offer
$NTLA $BEAM $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY
3
8
55
$MREO WOW THIS IS BIG the rumor have been confirmed that Onxcerna Therapeutics is in process being sold
$MREO will reeive $300M milestone payment who ever acquired Onxcerna Therapeutics
OncXerna Therapeutics CFO confirmed the rumor
"things were great while I was there but
$MREO 💪 I heard that OncXerna is being acquired and huge upside for MREO if the deal gets done
OncXerna Therapeutics, the company being sold and we should hear soon an announcement.
reminder: $MREO could receive $300 million in milestones plus royalties who ever acquired
5
5
24
0
2
51
$MREO 🤩 extremely bullish
setrusumab lead asset on $RARE pipeline could be value $2B+ but unfortunately currently no value on Mereo valuation.
What is baked into the price of $RARE
Cash per share $10
Setrusumab $16 Per share & 0 for $MREO
We believe upcoming data in
4
6
45
$MREO the most important/binary catalyst in near term is Setrusumab phase 2 Osteogenesis Imperfecta 12 months fractures results. I will provide more information next week when we can expect the results.
$XBI $IBB $VKTX $CYTK
1
3
48
$MREO grand slam presentation by Kristen Kluska
2 top picks and $MREO is one of them
-Underappreciated and undervalued company in universe
-Very bullish on Alvelestat phase 3 in
#AATD
* very relaxed primary endpoints by FDA & EU
$WVE $NTLA $BEAM $KRRO $CYTK $VKTX $XBI $IBB
3
6
47
$MREO $RARE grand slam
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD)
12
0
45
$GSK to buy Bellus Health $BLU for $2bn for 1 asset chronic cough drug peak sales $574M by 2028
$MREO how much is worth it ? Absolutely certain that the pipeline is better than $BLU
$MREO have 6 assets Vs $BLU 1
$MREO assets:
Lead assets in late stage
1) Setrusumab
Another day another M&A, this time from $GSK for chronic cough player Bellus. Consensus has sales of $574m by 2028 for BLU-5937, according to
@evaluatepharma
. Another helpful revenue stream hopefully on the way, after GSK yesterday confirmed gepotidacin will be filed this year.
1
0
6
9
6
43
$MREO 🤩
$AMGN $6Bn blockbuster drug Prolia/Denosumab monoclonal antibody new study shows that did not reduce fracture compared with bisphosphonates.
prolia - did not reduce fracture compared with bisphosphonates in postmenopausal women
-Prolia patient cliff will happen
3
11
43
$MREO strong fundamentals
the stock is trading $.71 which is a mind boggling to me
The financial report looked good.
$88M market cap
$68M in cash
Cash runway until 2026
2 rare disease late stage assets
1) Setrusumab Osteogenesis Imperfecta market opportunities $1.7B
9
3
43
$MREO & $AUPH should be next to be acquired. Both companies strong financially and no need to raise money
Both companies already rumored to be acquired by big pharmas
$XBI $IBB $IMGN
3
3
44
$MREO Current market cap $471M:
IMO BUY OUT PRICE MINIMUM $2BN / $15
LEAD ASSET POTENTIAL VALUATION
Alvelestat phase 3 ready
#AATD
VALUE $1.5b - $2.bn
similar to $INBX INBRX-101 acquired for $2.2Bn
Setrusumab- Osteogenesis Imperfecta bone disease value +$1Bn - similar
3
6
43
$MREO Tomorrow I expect fireworks at Fireside Chat Leerink Partners
$XBI $IBB
1
5
42
$TRKA potentially revisit the $.99 ? Eliminated toxic warranties.
450M in revenue in 2023
Cash flow positive in 2023
$81M current market cap does not make sense
1
7
39
$MREO 💪great 1st QTR 2024
-Cash runway until 2026
-Milestone payment should be coming from $RARE
-$175M shelf offering is not effective yet.
its just formality and clean S3
no toxic financing: preferred stocks, warrants or Subscription rights
nothing to worry
$XBI $IBB
0
4
42
$ATNM Full Data set very impressive
achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients
3
9
42
$MREO 💪 GREAT NOTE BY Needham MREO – BD WILL BE IN FOCUS THIS YEAR
1) Partnering Phase III Ready Alvelestat in
#AATD
could be a Meaningful Driver:
IMPACT: MED-HIGH
CONFIDENCE: MED
2) PHASE 3 Setrusumab Osteogenesis Imperfecta READ OUT 2024/2025
IMPACT: HIGH
CONFIDENCE: HIGH
3)
2
6
41
$MREO sent email today to rubric capital hand picked board members about the Etigilimab
#TIGIT
asset similar to $ITOS EO-448 which was licensed to $GSK for $625M upfront +1.45Bn in milestone payments
Despite terrible current biotech conditions $MREO is very unique company
4
2
40
$MREO $320M market cap extremely cheap and I have raised my price target to $15-$20
based on recent acquisition of $RYZB for $4.1Bn by $BMY
$EYPT $OCUL $XBI $IBB $TPST $ARDX $WVE $INBX $GSK $KRRO $BEAM $NTLA $CNTA $VRTX $NVO $AZN $NVS $KRYS $BMY $LLY $IMGN $INZY $tgtx $AUPH
3
5
40
$MREO 👍
inside buy at open market price On June 16, 2023, Dr. Denise Scots-Knight purchased 200K shares at $1.42. The CFO scooped up 10K shares at $1.34
The transaction occurred 2 days after rubric capital purchased 1.25M shares at open market price
$XBI $IBB $INZY $XFOR
5
7
39
$ATNM great results
OS (6.4 mo vs 3.2 mo)
PFS at 6 Months lomab 26% vs .02 %CC
Better safety profile this grandslam home run
6
2
38
$ATNM new report from HCW. I will share it with my followers first. Let me know who is interested
29
1
38
$MREO $543M Market cap: Cantor described the current valuation "undervalued in Universe" truly unique pipeline.
" 1-2 punch" rare disease (Setrusumab and Alvelestat) combined assets could be worth minimum $15 per share.
other asset could be valued another $5 per share
$MREO Interesting your thesis was alvelestat and mine always was Setrusumab- now both coming together- nice 1-2 punch going forward with others in pipeline $MREO
3
5
41
1
3
36
1/ $MREO great note by Analyst Julian Harrison of BTIG PT $6
Analyst Buy rating due to a combination of factors positive clinical advancements of Mereo Biopharma Group Plc’s lead drug,
#setrusumab
,and its potential impact on osteogenesis imperfecta (OI)
$XBI $IBB $RARE $AMGN
3
7
36
$MREO no panic but 12 days in row the stock price closed in red its time to engage with Centerview. The chart looks bullish ahead to next week binary catalyst
$XBI $IBB
5
2
35
$MREO fair value is $10
@PersimmonTI
valuation on $MREO
Risk-adjusted, $800mm seems about fair for acquisition at current stage:
- $450mm P3 ready Alvelestat
- $300mm EU rights & royalties Setrus
- $50mm TIGIT, and Navi, etc.
My valuation:
I will accept $800M BO deal
4
3
35
$MREO analysts price target is irrelevant IMO. The company is worth minimum low double digit
take look at $AMAM analysts price target before acquired by $JNJ for $28
Goldman Sachs had PT of $2→ $6→$9 before acquired for $28
Baird had PT of $12
$XBI $IBB
$MREO the next few months will be transformative for the company
multiple updates on Setrusumab program
1) PHASE 3 Setrusumab Osteogenesis Imperfecta enrollment completion in March 2024
2) PHASE 2 Osteogenesis Imperfecta fractures data
all analysts CONFIDENCE LEVEL are HIGH
3
3
23
2
2
34
$MREO $540M Market cap still massively undervalued
many Big catalysts near term
Setrusumab - phase 3 enrollment completion 1st qtr
Setrusumab - phase 2 (12 months fracture rates data) 2nd qtr EXTREMLY IMPORTANT
Alvelestat- $INBX sells of INBRX-101
#AATD
for $2.2Bn increase
1
2
34
$MREO PHASE 2 Setrusumab 12 month fractures data the company already knows the results on the open-label trial. Some of the patients have been 24 months on Setrusumab treatment . 2H 2024 data is just formality for the company. cheers
$XBI $IBB
$MREO Eric Crombez, M.D., Chief Medical Officer
When talking about Setrusumab and path forward.
23:50 or so
" I have trained as a bio chemist, I have never this type of clarity in signals" (in regards to EFFICACY)..
He also hints there are no fractures after time on Setru as
5
10
72
1
2
34
$MREO CURRENT MARKET CAP $433M/ SP $3.09
- many binary catalysts in 2024
FLOOR BUY OUT PRICE TARGET +$2bn/$14 per share
-IMHO $5bn - $7Bn in 12month - 18 Months similar as $RETA Acquired for $7.3Bn
$FUSN ACQUIRED FOR $2.4bn/ $24 per share by $AZN
Sept 2023 $FUSN SP TRADED
0
3
34
$MREO still extremly undervalued company . IMHO the company should be valued around $5bn -$7bn / $30-$40 per share
$BIIB acquired $RETA for $7.2Bn ultra rare disease drug addressable market 5k people
$MREO lead asset Setrusumab addressable market 50k people
$XBI $IBB
0
6
33
$MREO if SETRUSUMAB gets approved in OI the valuation will skyrocket at least +$3Bn
Potentially Buy out PT would be $30-$45 SETRUSUMAB peak sale US +$2Bn &+$1bn EU
$RYTM the SP from $3s to $50 after approval
$RETA the SP from $21s & acquired after approval $172
$XBI
just how important -
#SETRUSUMAB
is for $RARE $MREO cantor believe this is yet to be reflected in stocks, as our current base case model and 100% PoS of OI alone would increase our DCF to $129, roughly 3x where the stock is trading today! For $RARE - assuming $MREO 3x also??
2
3
28
5
1
33
$TRKA
Good fundamentals
Peter Coates Billionaire Co-founder of the United Kingdom-based online sports betting company Bet365 Group Ltd
Disclosed 10.483M shares ownership cost roughly $.82
Thomas Mariancacci Founder of Converge disclosed 7M shares ownership
Per annual
1
6
31
$MREO 💪 Its seems that institutional investors loaded up
Standard Life Aberdeen disclosed new position 1,551,082 shares on $MREO
$NTLA $BEAM $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY $ARDX $XBI $IBB $NVO $MOR $FDMT $AUPH $SNAP $GILD $SMMT $exel $lly
$MREO 👍
Actvist SOLEUS disclosed 9,677,419 shares 8.27% ownership on February 6, 2024
$NTLA $BEAM $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY $ARDX $XBI $IBB $NVO $MOR $FDMT $AUPH $SNAP $GILD $SMMT $exel $lly
2
2
26
0
2
32
$MREO its official transition into Nasdaq is completed. Now company will only comply with SEC rules
Let the bidding war begin
$XBI $IBB $ATHA
$MREO transition into Nasdaq open the door for potential deal.
the company will be transitioning from its foreign private issuer to US Listing only in January 1 2024. It will make it easier for potential suitors to acquire the company.
Probably the company corporate
3
2
20
2
5
33
$MREO 🤩
New position Soleus Private Equity Fund filed 13G on July 26
Roughly 9,677,419 shares 7.5% equity stake.
$XBI $IBB $HRTX $INZY $XFOR $ARDX $GRTX
2
6
33
$MREO 🤩
2 big buys orders filled.
487,827 at $1
500,000 at $1
$XFOR $INZY $XBI $IBRX $CNSP $VKTX $ISEE $PLX $ADRX $CDTX $SGMO
2
3
32
$MREO
1st 2023 QTR 13F
Citi Group
Added 1.129M shares building big position
JP Morgan
Added 281K shares
Tejara Capital building big position
Added 247K shares owns 2.435M shares
Acadian Asst
Added 191.899K shares
$XBI $IBB $INZY $ARDX $XFOR $IBRX $KRBP $IMGN
2
2
32
$ATNM maxim group PT $35
P3 SIERRA Data Presented at ASTCT; BLA filing Next, Potential Early Access Program Too
1
4
32
$MREO institutional investors accumulation Continues
MONACO ASSET MANAGEMENT increase their position on $MREO
$NTLA $BEAM $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY $ARDX $XBI $IBB $NVO $MOR $FDMT $AUPH $SNAP $GILD $SMMT $exel $lly $vktx
$MREO 💪 Its seems that institutional investors loaded up
Standard Life Aberdeen disclosed new position 1,551,082 shares on $MREO
$NTLA $BEAM $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY $ARDX $XBI $IBB $NVO $MOR $FDMT $AUPH $SNAP $GILD $SMMT $exel $lly
0
2
32
0
2
32
$MREO 👍 buy out coming
$RARE Emil D. Kakkis, CEO continues to pounded the table on Setrusumab /UX143
2023 will be focus on two of our key programs
1) UX143 in osteogenesis imperfecta
2) GTX-102 in Angelman syndrome could have safety issues not bullish
$XBI $IBB
0
2
31
$MREO folks are not paying attention how cheap the current valuation is.
IMO no way this company will be sold less than $12 per share after $INBX $2.2bn deal for INBRX-101
#AATD
asset with $SNY
$AUPH $KALV $MREO $FOLD $INSM $ANTH $LLY $NOV $azn $VRTX $BEAM $NTLA $KRRO
0
3
31
$MREO wow the resolution was approved by 99.64%. The resolution make it easer for potential suitors to acquired the company and comply only with SEC rules. let the bidding war begins
$XBI $IBB
0
5
32
1/ $MREO $0 value is reflecting the current valuation
3rd late stage asset very attractive Acumapimod focused in inflammatory disease phase 3 ready in exacerbations of chronic obstructive pulmonary disease (AECOPD)
market size by 2030: $35Bn
@ragingbullcap
@QuilchenaPark
@ragingbullcap
$MREO Great thread: I will provide more details on 3rd late stage asset Acumapimod p38 MAP kinase.
0
0
13
1
8
32
$MREO stock price continue to steadily increasing.
I had/ continue to have strong conviction on the stock
-$422M market cap PATHETICALLY LOW
- Price target Now $10 very Conservative for rare disease pipeline
-Price target when Setrusumab approved similar valuation as $RETA
Cantor - 2 different analysts covering $RARE & $MREO - undervalued assets on both
1
8
43
1
4
30
$MREO WOW full court pressure continues from shorts, MM, day traders: 😂 nothing new
Strong fundamentals:
-Cash runway into 2026
-Activist control boardroom
-Buy out is just matter of time
No panic and haven’t sold any shares.
$XBI $IBB $AMAM $HARP $CYTK $ARQT $ARDX
$MREO something is brewing maybe deal soon ? Who would be $NVS or $AZN $GSK
$XBI $IBB $AMAM $HARP $CYTK $ARQT $ARDX $INZY $WVE $SMMT
0
1
16
1
3
30
$MREO $RARE 💪💪 phase 3 trial Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta (Cosmic) updated clinical trial gov 04/09/2024
on track to complete the enrollment very soon.
$XBI $IBB $AMGN
$MREO Setrusumab will be the front and center TODAY $RARE will report earnings
phase 3 trial Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta (Cosmic) updated clinical trial gov 2/13/2024
on track to complete the enrollment 1st half 2024
0
2
12
1
2
31
$MREO Rubric capital the largest share holder continues to load up. added 433,695 shares this week at open market
today filed SCHEDULE 13D/A RUBRIC increased the ownership into 13.15%
Purchase 290,061 shares at $1.7762 10/27/2023
Purchase 143,634 shares at $1.8142
1
9
31
$MREO $567M current market cap:
$2B-$4Bn deal is peanuts to big pharmaceuticals companies
🤩 Big pharms $500B in firepower for deals & facing huge patent cliffs in 2024-2028
$XBI $IBB
That's worth repeating! Big pharma spent $178 bil on M&A in 2023, but Stifel estimates that the top 16 pharma still have over $500 bil in firepower for more deals, which they need to spend to cover the massive patent cliff that's coming up! $XBI 🚀
2
15
60
0
3
30
$MREO 👍
the biggest deal maker in biotech industry Baker Bros 9.9% ownership on $MREO
Baker Bros filing 13GA disclosing ownership of 69,359,359 shares9.99%
$XBI $IBB $OCGN $XBI $IBB $RMED $BBAI $SRZN $CTMX $EXPR $MSGM $KPRX $HOTH $SRZN $CLNN $COMS $TOPS $ARDX $AVRO $SMMT
2
3
31
$MREO the company could report 4th qtr earnings this week before next Monday deadline
IMHO potentially major updates will be reported on 4th qtr earning report
$BPMC $INZY $XBI $IBB $VINC $BIIB $VRTX $ITOS $NVS $lly $NVO $AMGN $PDSB $SMMT
$MREO reminder 4th qtr earning report is due by March 31:
IMHO potentially major updates this month will be reported on 4th qtr earning report
1) Alvelestat phase 3 trial design: FDA meeting took place this year:
2) setrusumab Orbit Phase 3 expected to be fully enrolled in the
2
3
21
2
2
31
$MREO reminder very important KOL conference tomorrow hosted by Cantor
@semodough
tweet ⬇️
“Cantor
#Biotechnology
: Alpha-1 Antitrypsin Deficiency Webinar Tuesday, January 30 at 1:30 PM ET $MREO $ARWR $INBX •Highlight MREO's (OW, K. Kluska) alvelestat (neutrophil elastase
Cantor
#Biotechnology
: Alpha-1 Antitrypsin Deficiency Webinar Tuesday, January 30 at 1:30 PM ET $MREO $ARWR $INBX •Highlight MREO's (OW, K. Kluska) alvelestat (neutrophil elastase inhibitor) program (including Phase 2 data) in AATD-associated lung disease moving into Phase 3.
1
6
44
1
2
31
1/ $MREO another bullish note from Baird "has maintained their bullish stance on MREO stock"
Robert W. Baird analyst Jack Allen
Buy Rating Affirmed for Mereo Biopharma on Strong Financials and Promising Pipeline Progress
$XBI $IBB $RARE
$MREO $5 soon. PT between $6 (BTIG) and $8 (Baird/Leerink). Potential
#AATD
deal could unlock hidden value in the pipeline of the company imo. $INSM $VRTX $KRYS $WVE
0
1
14
1
3
31
$MREO amazing conference and unbelievable results, potentially curative therapy and sadly the stock price is trading $1.54 is ridiculous.
$XBI $IBB
2
0
31
Bold prediction $MREO $AUPH will be acquired in 2023/ 1st half in 2024
$XBI $IBB
6
0
30
👀 Potential acquisition target
$MREO diversified portfolio & multiple partnerships
EV $30M
– Rare disease + oncology
– multi corporate partners $AZN $RARE $NVS
– Multiple shots on goal
– cash runway 2026
– Activist rubrics appointed 4 BoD
$MREO the cheapest late stage
$APLS Apellis Pharmaceuticals rare disease company Is Said To Attract Takeover Interest - Bloomberg
0
0
0
3
6
30
$MREO fireworks happened at leerink Conference yesterday :
1) Setrusumab: preparation for potential commercialization is underway in EU
-Already identified 10K patients (pediatrics 5K + Adults 5K) out of 30,000 patients
- Setrusumab EU/UK pricing similar to Crysvita
$MREO Tomorrow I expect fireworks at Fireside Chat Leerink Partners
$XBI $IBB
1
5
42
0
5
30
$MREO Alvelestat has validated path forward into phase 3 trial:
-roughly 1,700 patient have been dosed with Alvelestat so far
- 2 Phase 2 Trials of alvelestat in
#AATD
-Lung Disease completed roughly 160 patients recruited
$INBX - INBRX-101 completed only 1 phase single arm
1
4
30
$MREO whoops Rubric did it again today filed SCHEDULE 13D/A by Activist Rubric Capital increased the ownership into 13.63%
RUBRIC Capital hand picked 4 board seats
recent purchased at open market
Purchase 437,624 sh at $2.055 11/6/2023
Purchase 78,089 sh at $2.05
$MREO Activist Rubric added again last week Thursday & Friday
-yesterday filed SCHEDULE 13D/A by Activist Rubric Capital increased the ownership into 13.32%
recent purchased at open market
Purchase 78,089 sh at $2.05 11/2/2023
Purchase 12,178 sh at $2.05 11/3/2023
0
3
28
0
3
30
i agree $MREO is at least "~4x undervalued" IMHO the company is worth at least $20
or
$2.5bn peak sales Setrusumab & Alvelestat is extremly conservative @ standard 3 multiplier the company value $7.5Bn/ $45 shares
$RETA Acquired @ 7 multiplier by $BIIB
$XBI $BMY $nvs
$MREO finally breaking out of the range it has been stuck in for 6 months. IMHO, it is ~4x undervalued! $XBI
0
0
18
1
3
30
$MREO
Feng Biosciences, Inc in 4th QTR . completed a restructuring and recapitalization and closed on a refinancing
-Under the global licensing agreement with Feng Biosciences, Mereo is eligible to receive up to $300 million in future clinical, regulatory and commercial
1
1
29
My favorite 3 stocks heavily discounted & misunderstood.
Rare disease/ oncology
$MREO
Gene therapy
$AVRO
RNA
$PRQR
$XBI $IBB
3
1
27
$MREO 💪
WOW ADAGE CAPITAL PARTNERS reports 9,250,000 shares 1100% increase in ownership of $MREO on February 5,2024
$NTLA $BEAM $KRRO $CYTK $VKTX $XBI $IBB $SNY $NVS $AZN $INZY $ARDX $XBI $IBB $NVO $MOR $FDMT $AUPH
0
3
29
$MREO I will send an email to Board members about Roche positive phase 3 tigit trial
$XBI $IBB
1
1
29
$MREO $469M market cap vs $INSM $7.14Bn
-Both companies seek lung disease indication BUT $mreo is 15 times cheaper than $INSM let that sink in
@AstraZeneca
is the loser because both drugs were dumped by $AZN ( $insm Brensocatib and $MREO Alvelestat)
$XBI $NVS $vrtx
1
4
29
tomorrow Cantor Roundtable to Discuss Alpha-1 Antitrypsin Deficiency Landscape and Clinical Development
Analysts lineup
Kristen Kluska $MREO LUNG 4.6/5 ★★★★★
Kristen Will discuss tomorrow
alvelestat (neutrophil elastase inhibitor)
(including Phase 2 data) in
$MREO reminder very important KOL conference tomorrow hosted by Cantor
@semodough
tweet ⬇️
“Cantor
#Biotechnology
: Alpha-1 Antitrypsin Deficiency Webinar Tuesday, January 30 at 1:30 PM ET $MREO $ARWR $INBX •Highlight MREO's (OW, K. Kluska) alvelestat (neutrophil elastase
1
2
31
2
3
29
$MREO $RARE to Report Second Quarter 2024 Financial Results on August 1, 2024
👁️ on Setrusumab phase 3 trial updates
$XBI $IBB
5
1
29
$MREO
@Pharmdca
Continue to pound the table on Mereo today tweet " another gem 💎 still way undervalued vs potential in large two indications"
reminder folks he punded the table on $TRIL at .33 and got acquired at $18.5 and $VKTX at $8s and now is trading $83S
$XBI $IBB $PDSB
bold predication but very possible could bcome true
$MREO current market $522M Potentially the next $RETA Valuation $7.2Bn:
1) Alvelestat- first-in and Best in class
#AATD
oral Drug
2) Setrusumab- best in class in Osteogenesis Imperfecta
Potential suitors: $AZN $NVS $VRTX
0
4
13
1
6
29
Rubric capital reported 1st QTR 13F 2023
no changes in 1st qtr
#1
$MREO 15.3% ownership
#2
$HRTX 9.85 ownership
#3
$TRVI 9.46% ownership
#4
$VINC 1.82% ownership
Reduced the position significantly:
$KPTI -46%
$TXMD -32%
Closed out the position
$MRNS
$CTMX
$SELB
$MREO very good news Rubrics capital disclosed May 12 1st qtr 13F holdings: No changes & continued to hold huge position.
$MREO 15.30% Ownership
Current stock price $1.15
cost basis for Rubric capital $2.58 -
3
4
49
2
6
29
$MREO great pipeline and current valuation still undervalued. some FOLKS may ask why ?
Mereo has 3 similar MOA drugs combined could be valued Billions.
will provide more details soon
$XBI $IBB
$MREO still extremly undervalued company . IMHO the company should be valued around $5bn -$7bn / $30-$40 per share
$BIIB acquired $RETA for $7.2Bn ultra rare disease drug addressable market 5k people
$MREO lead asset Setrusumab addressable market 50k people
$XBI $IBB
0
6
33
0
3
29
$MREO Activist Rubric added again last week Thursday & Friday
-yesterday filed SCHEDULE 13D/A by Activist Rubric Capital increased the ownership into 13.32%
recent purchased at open market
Purchase 78,089 sh at $2.05 11/2/2023
Purchase 12,178 sh at $2.05 11/3/2023
$MREO today filed SCHEDULE 13D/A by Activist Rubric Capital increased the ownership into 13.25%:
recent purchased at open market
Purchase 44,575 shares at 1.94 10/31/2023
Purchase 99,851 shares at 1.9811 11/01/2023
Purchase 290K shares $1.77 10/27/2023
Purchase
0
4
25
0
3
28
$MREO Folks are underestimating Mangrove Partners big position. Rubrics capital + Mangrove + Soleus Private Equity + Suvretta Capital+ Rock Springs Capital Combined companies hold roughly 40% ownership.
it reminds me rubric + Velan-Repertoire when both companies
$MREO another activist 🤔Mangrove Partners new position 5,531,547 shares at $1.32 4.72% ownership date reported 08/14/2023
7
7
41
1
5
28
$MREO We have built big retail investors coalition in biotech sector that have not seen before. We are working very hard behind the scenes to ensure that management listen to us and deliver shareholder value. Stay tuned
4
0
26
$MREO great results at
#ESMO2023
will provide more information tomorrow.
I’m long as well and my largest position
WILL NOT SELL ANY SHARES BELOW $5
$XBI $IBB
👇
$MREO impressive data from anti TIGIT antibody at ESMO. 3 complete responses in cervical cancer. Long (my largest position).
0
7
47
2
2
28
$MREO speechless the stock price is trading $3s and market cap $465M
2 late stage assets
Clean balance sheet & low cash burn
$INSM stock price is trading $52s market cap $7.7Bn
Toxic balance sheet
1.6Bn total liabilities
$939M long term debt
High burn rate
$XBI $IBB
$MREO $469M market cap vs $INSM $7.14Bn
-Both companies seek lung disease indication BUT $mreo is 15 times cheaper than $INSM let that sink in
@AstraZeneca
is the loser because both drugs were dumped by $AZN ( $insm Brensocatib and $MREO Alvelestat)
$XBI $NVS $vrtx
1
4
29
0
4
28
$MREO new report published today by Needham analyst Gil Blum
Needham analyst Gil Blum raised the price target on Mereo BipPharma Group (NASDAQ: MREO) to $6.00 (from $5.00) while maintaining a Buy rating. The analyst commented: 'Enrollment in the pivotal Orbit study of
0
2
27
$MREO AH Bid :$3.84 X 100 Ask:$40.00 X 8656
$40 PT roughly $6Bn valuation is possible ? god knows best but I have seem crazy things happened before
IMHO $MREO acqusition price target should be similar to $RETA $7.2bn
$RYTM $4 ➡️$50
$RNA $5 ➡️ $48
$VKTX $2 ➡️ $100
$XBI
1
3
28
$MREO $RARE
Today cantor deep dive was great. Looking forward into 3rd qtr phase 2 data
$XBI $IBB
$MREO $RARE very important deep dive tomorrow 10:30am
Fireside Chat with Ultragenyx Pharmaceutical (RARE) focusing on Osteogenesis Imperfecta (OI):
$BPMC $INZY $XBI $IBB $VINC $BIIB $VRTX $ITOS $NVS $lly $NVO $AMGN $PDSB $SMMT
1
2
18
0
2
28
$MREO New article published for the first time at frontiers
"A novel in vitro cell model of the proteinase/antiproteinase balance observed in alpha-1 antitrypsin deficiency"
$XBI $IBB $WVE $NTLA $BEAM $NVO $KRRO $INSM $GSK $NVO
1
0
28
I canceled my
@SeekingAlpha
subscription because of poor job done by editors reviewing the articles before published. Stephen Ayer’s has no business writing biotech articles at
@SeekingAlpha
I urge everyone cancel their subscription as well.
$XBI $IBB
9
0
28
$ATNM great results
#ASH20
#135
High Doses of Targeted Radiation with Iomab-B Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in Randomized Ph 3 Sierra Trial for Rel/Ref AML
#leumsm
#bmtsm
Great work by
@BGyurkocza
@sloan_kettering
0
4
17
1
2
27
$MREO $558M market cap is ridiculous low
$MOR potential buyout rumor by $NVS for $10Bn
$MOR license potential blockbuster drug Setrusumab to $NVS for nothing
⬇️
$NVS license Setrusumab to $MREO
$MREO will be acquired soon $2B /$ 12-$15 per share ? $AZN $NVS
0
1
28
$MREO the cheapest rare disease company
#1
$MREO SP $1.28 $160M MC
2 potentially blockbuster assets
1) Setrusumab currently in P3 Osteogenesis Imperfecta $1B+ peak sales potentials
2) *Alvelestat phase 3 ready in severe Alpha-1 Antitrypsin Deficiency: peak sales $4B+
One of the reasons rare disease companies like $BMRN and $ALNY have premium valuations relative to their peers is orphan drug pricing (higher margins) and limited competition.
Something to consider if companies like $XFOR or $MREO can get FDA approval down the road.
4
3
32
1
0
28
$MREO is not another $PDSB or $AMLX
$MREO thesis has become stronger despite the stock price -33% is great BUY opportunity IMHO
3 pivotal programs : near term catalysts
1) Setrusumab- 2 PHASE 3 TRIALS NEAR COMPLETING THE ENROLLMENT IN IO (Expected 1st qtr)
2) Alvelestat -
$MREO (NP)
Is not another $PDSB (long catalyst desert) or $AMLX (highly binary, low PoS asset) IMO
Setrusumab data in OI already impressive w/ clear path to value creation via P3 data then license remaining rights (or BO)
Values in AATD space going up ($SNY acquiring $INBX for
7
5
45
1
2
27
$MREO August corporate presentation
-Extremely hard to justify current low market cap of $156M
-Cash: $60M cash runway into 2026
- Multiple activists: rubrics Capital, Mangrove Partners
Corporate partners: $AZN $NVS $RARE
2 rare disease in late
1
3
27
My top 3 ideas for
#biotech2024
: IMO could be acquired near term.
$MREO the cheapest rare disease
$RARE the cheapest rare disease
$AUPH
$XBI $IBB
OPPY Top Ten Ideas for
#Biotech2024
Oh, The Places We'll Go in 2024 Top Ideas: $ALPN, $AMGN, $CRNX, $CYTK, $DYN, $FUSN, $GILD, $SLNO, $SVRA, $VKTX
1
6
36
0
2
27
$MREO
NEEDHAM April 21, buy rating
Price target $5 400.00% Upside
2 important catalyst in 2nd qtr:
setrusumab Phase 2 data and Phase 3 transition (guided for mid-2023) and the initiation of a trial in pediatric patients (ages 2-5 years) to assess whether a higher
3
2
26
$MREO Major win for Phase 3 Setrusumab in Osteogenesis Imperfecta is the real deal and unfortunately is underappreciated/undervalued
the only real competitor to Setrusumab is $AMGN blockbuster drug denosumab/Prolia quarterly revenue $900M
@Amgen
terminated Prolia
$RARE $MREO
#Setrusumab
's Key Competitive Threat $AMGN is Fading Quickly per cantor - more on bear thesis falling apart
4
8
52
1
2
27
$MREO $RARE Setrusumab willl be ideally replacement for
@amgen
$amgn Prolia/Xgeva $4.6BN facing patent expira in 2025/2026
Setrusumab could be +$5Bn drug under big pharmas control.
other inidcations osteoporosis & various cancers Multiple myeloma &Breast cancer
$XBI $IBB
#bullish
on biotech patent cliff is approaching
Keytruda 2028 $MRK
Opdivo 2028 $BMY
Revlimid 2025 & 2026 $BMY
Eylea 2025 & 2026 $REGN
Stelara 2025 & 2026 $JNJ
Dolutegravir 2027 & 2029 $GSK
Ibrance 2027 $PFE
Prolia/Xgeva 2025 & 2026 $AMGN
Cosentyx -2025 & 2026 $NVS
$XBI $IBB
0
1
7
0
2
27
$MREO IMHO pipeline is worth +$4bn vs Curent market cap $386M
reminders: 2023 beaten down stocks that recovered nicely in 2024
$JANX Current SP $52 ➡️ $5.65 Nov 2023
$ALPN ACQUIRED $65 ➡️ $6.7 May 2023, many setbacks in 2023
$VERA Current SP $50 ➡️$6 Apr 2023
$XBI $IBB
1
0
27
$MREO I will provide potential near term catalyst later today. Stay tuned
$XBI $IBB
1
3
27